Thrive Capital Management (Pennsylvania)’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $334K | Buy |
1,799
+370
| +26% | +$68.7K | 0.1% | 141 |
|
|
2025
Q1 | $299K | Buy |
+1,429
| New | +$299K | 0.18% | 98 |
|
|
2024
Q4 | – | Sell |
-1,669
| Closed | -$330K | – | 97 |
|
|
2024
Q3 | $330K | Sell |
1,669
-11,081
| -87% | -$2.19M | 0.16% | 146 |
|
|
2024
Q2 | $2.19M | Buy |
12,750
+5,085
| +66% | +$872K | 1% | 20 |
|
|
2024
Q1 | $1.4M | Buy |
7,665
+4,583
| +149% | +$834K | 0.74% | 20 |
|
|
2023
Q4 | $478K | Sell |
3,082
-97
| -3% | -$15K | 0.26% | 62 |
|
|
2023
Q3 | $474K | Sell |
3,179
-6
| -0.2% | -$894 | 0.26% | 63 |
|
|
2023
Q2 | $429K | Sell |
3,185
-292
| -8% | -$39.3K | 0.24% | 69 |
|
|
2023
Q1 | $549K | Buy |
3,477
+145
| +4% | +$22.9K | 0.35% | 58 |
|
|
2022
Q4 | $539K | Buy |
3,332
+99
| +3% | +$16K | 0.35% | 56 |
|
|
2022
Q3 | $434K | Buy |
3,233
+706
| +28% | +$94.8K | 0.29% | 61 |
|
|
2022
Q2 | $387K | Buy |
2,527
+368
| +17% | +$56.4K | 0.27% | 61 |
|
|
2022
Q1 | $350K | Sell |
2,159
-5,232
| -71% | -$848K | 0.21% | 64 |
|
|
2021
Q4 | $1M | Sell |
7,391
-7,794
| -51% | -$1.06M | 0.65% | 40 |
|
|
2021
Q3 | $1.64M | Buy |
15,185
+712
| +5% | +$76.8K | 1.21% | 21 |
|
|
2021
Q2 | $1.63M | Buy |
14,473
+5,121
| +55% | +$577K | 1.27% | 19 |
|
|
2021
Q1 | $1.01M | Buy |
9,352
+2,665
| +40% | +$288K | 0.95% | 26 |
|
|
2020
Q4 | $716K | Buy |
+6,687
| New | +$716K | 0.76% | 30 |
|